{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:56Z","timestamp":1794047456267,"version":"4.8.0"},"reference-count":35,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of thrombin substrates. Such differences may potentially result in clots with different structural and physical properties. A starting observation of incomplete wound closure in a patient on emicizumab prophylaxis led us to employ a relevant mouse model in which we noticed that emicizumab-induced clots appeared less stable compared to FVIII-induced clots. We therefore analyzed fibrin formation in vitro and in vivo. In vitro fibrin formation was faster and more abundant in the presence of emicizumab than in the presence of rFVIII\/rFVIIIFc. Furthermore, the time-interval between the initiation of fibrin formation and factor XIII activation was twice as long for emicizumab than as for rFVIII\/rFVIIIFc. Scanning electron microscopy and immunofluorescent spinning-disk confocal microscopy of in vivo-generated clots confirmed increased fibrin formation in the presence of emicizumab. Unexpectedly, we also detected a different morphology between rFVIII\/rFVIIIFcand emicizumab-induced clots. Contrary to the regular fibrin mesh obtained with rFVIII\/rFVIIIFc, fibrin fibers appeared to be fused into large patches upon emicizumab treatment. Moreover, fewer red blood cells were detected in regions in which these fibrin patches were present. The presence of highly dense fibrin structures associated with a diffuse fiber structure in emicizumab-induced clots was also observed when using super-resolution imaging. We hypothesize that the modified kinetics of thrombin, fibrin and factor XIIIa generation contribute to differences in structural and physical properties between clots formed in the presence of FVIII or emicizumab.<\/jats:p>","DOI":"10.3324\/haematol.2023.284142","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:21:28Z","timestamp":1701919288000},"page":"1836-1848","source":"Crossref","is-referenced-by-count":4,"title":["Differences in venous clot structures between hemophilic mice treated with emicizumab &lt;i&gt;versus&lt;\/i&gt; factor VIII or factor VIIIFc"],"prefix":"10.3324","volume":"109","author":[{"given":"Thibaud","family":"Sefiane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Maynadi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Escurola","family":"Ettingshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Muczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Heiligenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier D.","family":"Christophe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"62039","doi-asserted-by":"crossref","unstructured":"Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013; 93(1):327-358.","DOI":"10.1152\/physrev.00016.2011"},{"key":"62040","doi-asserted-by":"crossref","unstructured":"Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability. Arterioscler Thromb Vasc Biol. 2022; 42(8):931-941.","DOI":"10.1161\/ATVBAHA.122.317164"},{"key":"62041","doi-asserted-by":"crossref","unstructured":"Sillen M, Declerck PJ. Thrombin activatable fibrinolysis inhibitor (TAFI): an updated narrative review. Int J Mol Sci. 2021; 22(7):3670.","DOI":"10.3390\/ijms22073670"},{"key":"62042","doi-asserted-by":"crossref","unstructured":"Domingues MM, Macrae FL, Duval C. Thrombin and fibrinogen gamma\u2019 impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood. 2016; 127(4):487-495.","DOI":"10.1182\/blood-2015-06-652214"},{"key":"62043","doi-asserted-by":"crossref","unstructured":"Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998; 92(11):3983-3996.","DOI":"10.1182\/blood.V92.11.3983.423k51_3983_3996"},{"key":"62044","doi-asserted-by":"crossref","unstructured":"Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021; 397(10274):630-640.","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"62045","doi-asserted-by":"crossref","unstructured":"Sankar AD, Weyand AC, Pipe SW. The evolution of recombinant factor replacement for hemophilia. Transfus Apher Sci. 2019; 58(5):596-600.","DOI":"10.1016\/j.transci.2019.08.010"},{"key":"62046","doi-asserted-by":"crossref","unstructured":"Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019; 133(5):389-398.","DOI":"10.1182\/blood-2018-08-872291"},{"key":"62047","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Mahlangu JN, Kim B. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9):809-818.","DOI":"10.1056\/NEJMoa1703068"},{"key":"62048","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9):811-822.","DOI":"10.1056\/NEJMoa1803550"},{"key":"62049","doi-asserted-by":"crossref","unstructured":"Callaghan MU, Negrier C, Paz-Priel I. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242.","DOI":"10.1182\/blood.2020009217"},{"key":"62050","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022; 28(Suppl 4):103-110.","DOI":"10.1111\/hae.14524"},{"key":"62051","doi-asserted-by":"crossref","unstructured":"Batsuli G, Wheeler AP, Weyand AC, Sidonio RFJr, Young G. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: real-world retrospective multi-institutional cohort. Am J Hematol. 2023; 98(10):E285-E287.","DOI":"10.1002\/ajh.27039"},{"key":"62052","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017; 130(23):2463-2468.","DOI":"10.1182\/blood-2017-08-801662"},{"key":"62053","doi-asserted-by":"crossref","unstructured":"Zong Y, Antovic A, Soutari NMH, Antovic J, Pruner I. Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in vitro model of hemophilia A. TH Open. 2020; 4(2):e94-e103.","DOI":"10.1055\/s-0040-1710032"},{"key":"62054","doi-asserted-by":"crossref","unstructured":"Shimonishi N, Nogami K, Ogiwara K. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII. Haemophilia. 2020; 26(3):e97-e105.","DOI":"10.1111\/hae.13961"},{"key":"62055","doi-asserted-by":"crossref","unstructured":"Janbain M, Enjolras N, Bolbos R, Brevet M, Bordet JC, Dargaud Y. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: a preclinical study. Haemophilia. 2021; 27(6):1002-1006.","DOI":"10.1111\/hae.14435"},{"key":"62056","doi-asserted-by":"crossref","unstructured":"Schultz NH, Glosli H, Bjornsen S, Holme PA. The effect of emicizumab and bypassing agents in patients with hemophilia - an in vitro study. Res Pract Thromb Haemost. 2021; 5(5):e12561.","DOI":"10.1002\/rth2.12561"},{"key":"62057","doi-asserted-by":"crossref","unstructured":"Bravo MI, Raventos A, Perez A, Costa M, Willis T. Non-additive effect on thrombin generation when a plasma-derived factor VIII\/von Willebrand factor (FVIII\/VWF) is combined with emicizumab in vitro. J Thromb Haemost. 2020; 18(8):1934-1939.","DOI":"10.1111\/jth.14887"},{"key":"62058","doi-asserted-by":"crossref","unstructured":"Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018; 103(4):e181-e183.","DOI":"10.3324\/haematol.2017.185330"},{"key":"62059","doi-asserted-by":"crossref","unstructured":"Kizilocak H, Marquez-Casas E, Phei Wee C, Malvar J, Carmona R, Young G. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia. 2021; 27(1):164-172.","DOI":"10.1111\/hae.14213"},{"key":"62060","doi-asserted-by":"crossref","unstructured":"Atsou S, Schellenberg C, Lagrange J. Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab. J Thromb Haemost. 2024; 22(1):112-125.","DOI":"10.1016\/j.jtha.2023.09.017"},{"key":"62061","doi-asserted-by":"crossref","unstructured":"Ferriere S, Peyron I, Christophe OD. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020; 136(6):740-748.","DOI":"10.1182\/blood.2019004334"},{"key":"62062","doi-asserted-by":"crossref","unstructured":"Johansen PB, Tranholm M, Haaning J, Knudsen T. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules. Haemophilia. 2016; 22(4):625-631.","DOI":"10.1111\/hae.12907"},{"key":"62063","doi-asserted-by":"crossref","unstructured":"Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost. 2004; 30(2):205-213.","DOI":"10.1055\/s-2004-825634"},{"key":"62064","doi-asserted-by":"crossref","unstructured":"Lozier JN, Nichols TC. Animal models of hemophilia and related bleeding disorders. Semin Hematol. 2013; 50(2):175-184.","DOI":"10.1053\/j.seminhematol.2013.03.023"},{"key":"62065","unstructured":"Locke M, Receveur N, Kiialainen A, David T. In vitro investigation of emicizumab efficacy and mode of action in vWD type 2 and 3 samples. Res Pract Thromb Haemost. 2022; 6(S1):630."},{"key":"62066","doi-asserted-by":"crossref","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019; 119(7):1084-1093.","DOI":"10.1055\/s-0039-1688687"},{"key":"62067","doi-asserted-by":"crossref","unstructured":"Antovic A, Mikovic D, Elezovic I, Zabczyk M, Hutenby K, Antovic JP. Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. Thromb Haemost. 2014; 111(4):656-661.","DOI":"10.1160\/TH13-06-0479"},{"key":"62068","doi-asserted-by":"crossref","unstructured":"Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol. 2005; 131(5):645-655.","DOI":"10.1111\/j.1365-2141.2005.05820.x"},{"key":"62069","doi-asserted-by":"crossref","unstructured":"Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000; 96(3):988-995.","DOI":"10.1182\/blood.V96.3.988.015k57_988_995"},{"key":"62070","doi-asserted-by":"crossref","unstructured":"Kattula S, Bagoly Z, Toth NK, Muszbek L, Wolberg AS. The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations. J Thromb Haemost. 2020; 18(4):885-894.","DOI":"10.1111\/jth.14744"},{"key":"62071","doi-asserted-by":"crossref","unstructured":"Janbain M, Enjolras N, Bordet JC. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: a preclinical study. J Thromb Haemost. 2020; 18(3):584-592.","DOI":"10.1111\/jth.14694"},{"key":"62072","doi-asserted-by":"crossref","unstructured":"Leong L, Chernysh IN, Xu Y. Clot stability as a determinant of effective factor VIII replacement in hemophilia A. Res Pract Thromb Haemost. 2017; 1(2):231-241.","DOI":"10.1002\/rth2.12034"},{"key":"62073","doi-asserted-by":"crossref","unstructured":"Feller T, Connell SDA, Ari\u00ebns RAS. Why fibrin biomechanical properties matter for hemostasis and thrombosis. J Thromb Haemost. 2022; 20(1):6-16.","DOI":"10.1111\/jth.15531"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284142\/76386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284142\/77063","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11374\/76386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:23Z","timestamp":1794045923000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284142","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}